Ketamine is a powerful anesthetic and, at lower doses, a fast-acting antidepressant that works by blocking a key receptor in the brain, triggering a cascade of changes in neural signaling, mood, and consciousness. Originally approved for surgical anesthesia in 1970, it has since become one of the most versatile drugs in medicine, used in operating rooms, emergency departments, psychiatric clinics, and chronic pain centers. What it does depends almost entirely on the dose.
How Ketamine Works in the Brain
Ketamine’s primary target is the NMDA receptor, a gateway on brain cells that normally responds to glutamate, the brain’s most abundant chemical messenger. By blocking NMDA receptors on a specific type of inhibitory brain cell, ketamine essentially takes the brakes off glutamate signaling. The result is a surge of glutamate activity in the prefrontal cortex, the region responsible for mood, decision-making, and complex thought.
That glutamate surge sets off a chain reaction. It stimulates a different set of receptors (AMPA receptors), which allows calcium to flow into neurons and triggers the release of a growth factor called BDNF. BDNF is sometimes described as fertilizer for the brain: it promotes the formation of new synaptic connections between neurons, strengthens existing ones, and activates internal signaling pathways that build the structural proteins synapses need to function. Animal studies show that a single dose of ketamine increases markers of synaptic plasticity in the prefrontal cortex, including the growth of new dendritic spines, the tiny projections where neurons communicate with each other.
This is fundamentally different from how traditional antidepressants work. Most older medications target serotonin or norepinephrine and take weeks to produce noticeable changes. Ketamine bypasses that system entirely, acting on glutamate and physically remodeling neural connections within hours.
The Dissociative Experience
At moderate to high doses, ketamine produces dissociation, a state of altered consciousness where your sense of self, surroundings, and reality shifts significantly. People commonly describe feeling detached from their own body (depersonalization), feeling that the world around them is unreal (derealization), and experiencing distorted perception of time and sensory input. Some people report unusual bodily sensations, a profound sense of peacefulness, or a feeling of floating.
The intensity of these effects follows a clear threshold. At low, sub-dissociative doses (roughly 0.1 to 0.4 mg/kg given intravenously), ketamine produces mild sedation and pain relief without significant mental alteration. Once the dose crosses approximately 1 to 1.5 mg/kg intravenously, the full dissociative state appears abruptly rather than gradually. This sharp transition is one of ketamine’s defining pharmacological features.
Surgical Anesthesia and Sedation
Ketamine was first developed as an anesthetic, and this remains one of its core medical roles. At anesthetic doses (typically around 2 mg/kg intravenously for adults), it produces 5 to 10 minutes of complete surgical anesthesia with a single injection. When given as an intramuscular injection at around 10 mg/kg, it provides 12 to 30 minutes of anesthesia starting within 3 to 5 minutes.
Unlike most anesthetics, ketamine preserves breathing reflexes and maintains blood pressure. This makes it especially useful in emergency medicine, battlefield settings, and pediatric procedures where other anesthetics carry greater risk. It is one of the few anesthetics that can be given safely in resource-limited environments where ventilators may not be available.
Treating Depression
Ketamine’s antidepressant effects are its most studied new application. At sub-anesthetic doses, typically around 0.5 mg/kg delivered intravenously over 40 minutes, ketamine can produce noticeable mood improvement within hours. This rapid onset is remarkable compared to conventional antidepressants, which often require four to six weeks to take effect.
Research using brain imaging shows that ketamine’s early effects (within the first 30 minutes) involve broad changes across cognitive, sensory, emotional, and reward-related brain circuits. By 48 hours, the drug’s action becomes more targeted, normalizing connectivity in specific brain regions associated with depression, including the habenula (involved in processing negative experiences), the thalamus, and the hippocampus.
The FDA approved a nasal spray form of esketamine (a mirror-image version of the ketamine molecule) for two specific groups: adults with treatment-resistant depression who have not responded to at least two different antidepressants, and adults with major depressive disorder who have active suicidal thoughts with intent. The nasal spray delivers the drug with about 45 to 50% bioavailability, meaning roughly half the dose reaches the bloodstream compared to an intravenous infusion. It must be administered in a certified healthcare setting under observation.
Chronic Pain Management
Ketamine infusions have become an important option for chronic pain conditions, particularly complex regional pain syndrome (CRPS), a debilitating condition involving severe, persistent limb pain. The most studied approach involves sub-anesthetic doses (0.10 to 0.9 mg/kg per hour) given over several consecutive days in a monitored setting.
A typical inpatient protocol runs for 5 consecutive days. Outpatient protocols, which use shorter daily sessions, may require up to 10 days to achieve comparable pain relief. Doses are usually started low and gradually increased over the first few days. Consensus guidelines from major anesthesiology and pain medicine organizations recommend starting with a minimum of 80 mg infused over 2 hours or longer before deciding whether to continue treatment. The pain relief from a single course of infusions can last weeks to months, though the ideal number of sessions and long-term treatment schedules are still being refined.
Side Effects at Medical Doses
Short-term side effects during or immediately after ketamine administration are common but generally resolve quickly. They include nausea, dizziness, increased blood pressure, and the dissociative symptoms described above. Most people tolerate these effects without lasting problems, particularly at the lower doses used for depression and pain.
The more serious concern is what happens with repeated or heavy use over time, particularly to the bladder.
Bladder and Urinary Damage
Ketamine-induced cystitis is the most significant long-term risk associated with frequent ketamine use. It involves chronic inflammation of the bladder lining that causes painful urination, blood in the urine, an urgent and frequent need to urinate (including at night), and reduced bladder capacity. In severe cases, it can progress to scarring of the ureters and kidney damage.
The risk is closely tied to how much and how often someone uses the drug. Urinary symptoms occur in over 25% of people who use ketamine recreationally. Among frequent users, about 20% report cystitis-like symptoms, compared to roughly 7% of infrequent users. Overall, the rate of lower urinary tract symptoms in ketamine users is more than six times higher than in the general non-drug-using population. This damage appears to result from ketamine and its breakdown products directly irritating the bladder lining, and it can become irreversible if use continues.
At the much lower doses and infrequent schedules used in clinical settings for depression or pain, the risk of bladder damage is substantially lower, though it is not zero with long-term treatment protocols.
Recreational Use and Misuse
Outside of medical settings, ketamine is used recreationally for its dissociative and euphoric effects. At low recreational doses, users describe mild floating sensations and relaxation. At higher doses, the experience can become intensely disorienting, sometimes described as a “K-hole,” a state of near-complete dissociation where people feel entirely separated from their body and environment. Ketamine carries a real risk of psychological dependence with repeated use, and the bladder damage described above is primarily seen in recreational users who take the drug frequently and in uncontrolled amounts.
Ketamine is classified as a Schedule III controlled substance in the United States, meaning it has accepted medical uses but also recognized potential for misuse and dependence. Possession without a prescription is illegal.